2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-108976
    Raclopride tartrate 98185-20-7 98%
    Raclopride tartrate is a selective dopamine D2/D3 receptor antagonist with potential antipsychotic effects. Raclopride tartrate binds to D2 and D3 receptors with Kis of 1.8 nM and 3.5 nM, respectively.
    Raclopride tartrate
  • HY-108977
    VUF 8430 98021-17-1 98%
    VUF 8430 is a potent and selective histamine H4 receptor agonist with a Ki of 31.6 nM and an EC50 of 50 nM.
    VUF 8430
  • HY-108985
    Trazium esilate 97110-59-3 98%
    Trazium esilate (EGYT-3615) is an antidepressant, which influences the central dopaminergic system. Trazium esilate synergizes amphetamine, potentiates stereotypy and hypermotility. Trazium esilate blocks Apomorphine (HY-12723)-induced hypothermic and the stereotypy, and Bulbocapnine (HY-W436270)-induced cataleptic state. Trazium esilate enhances the effect of Norepinephrine (HY-13715) on isolated vas deferens of the rat.
    Trazium esilate
  • HY-109006
    Ilmetropium iodide 129109-88-2 98%
    Ilmetropium iodide is an anticholinergic agent. Ilmetropium iodide selectively blocks M-cholinergic receptors of bronchial muscle, reduces or prevents bronchoconstrictor response associated with both cholinergic stimulation, as well as the impact of the factors that provoke bronchospasm. Strength and selectivity of ilmetropium iodide action substantially exceeds Atropine sulfate (HY-B1205A) and Ipratropium bromide (HY-B0241).
    Ilmetropium iodide
  • HY-109064
    Loxicodegol 1211231-76-3 98%
    Loxicodegol (Oxycodegol) is a first-in-class, long-acting, orally active, and selective mu-opioid agonist with structural properties that reduce its rate of entry across the blood-brain barrier compared with traditional mu-opioid agonists.
    Loxicodegol
  • HY-109067
    Opiranserin 1441000-45-8 98%
    Opiranserin (VVZ-149), a non-opioid and non-NSAID analgesic candidate, is a dual antagonist of glycine transporter type 2 (GlyT2) and serotonin receptor 2A (5HT2A), with IC50s of 0.86 and 1.3 μM, respectively. Opiranserin shows antagonistic activity on rP2X3 (IC50=0.87 μM). Opiranserin is development as an injectable agent for the treatment of postoperative pain.
    Opiranserin
  • HY-109075
    Tasipimidine 1465908-70-6 98%
    Tasipimidine is an orally active and selective α2A-adrenoceptor agonist with a pEC50 of 7.57 for human α2A-adrenoceptors and an EC50 of 5.7 nM for rat α2-adrenoceptor. Tasipimidine can be utilized in research related to situational anxiety and fear.
    Tasipimidine
  • HY-109118
    Masupirdine free base 701205-60-9 98%
    Masupirdine free base (SUVN-502 free base) is a potent, selective, orally active, and brain-penetrating 5-HT6 receptor antagonist (Ki of 2.04 nM for human 5-HT6 receptor). Masupirdine free base has pro-cognitive effects on all stages of cognition (acquisition, consolidation, and retention), and can reverse Scopolamine (HY-N0296), MK-801 (HY-15084B)-induced and aging-related memory deficits. Masupirdine free base can be used in the research of Alzheimer's disease.
    Masupirdine free base
  • HY-109133
    Pecavaptan 1914998-56-3 98%
    Pecavaptan, a chemical probe, is an orally active and dual antagonist of V1a/V2 receptor (Ki=0.5 nM and 0.6 nM for human, respectively). Pecavaptan promotes an increase in urine production, which reduces the associated symptoms of water retention and edema.
    Pecavaptan
  • HY-109147
    Imnopitant 290297-57-3 98%
    Imnopitant is a NK1 receptor antagonist (WO2020132716, compound 1) .
    Imnopitant
  • HY-109149
    Lomardexamfetamine 1032291-80-7 98%
    Lomardexamfetamine (KP 106) is an orally active central nervous system stimulant composed of d-amphetamine and a ligand. Lomardexamfetamine can be used for the research of attention-deficit hyperactivity disorder.
    Lomardexamfetamine
  • HY-10933S
    CX516-d10 1286653-21-1 98%
    CX516-d10 is the deuterium labeled CX516. CX516 (BDP 12) is an ampakine and acts as an AMPA receptor positive allosteric modulator for the research of Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI).
    CX516-d10
  • HY-109514
    Imiglucerase 154248-97-2 98%
    Imiglucerase is a recombinant human glucocerebrosidase that glucosylceramide to glucose and ceramide. Imiglucerase can be used for the study of type 1 (non-neuronopathic) and type 3 (chronic neuronopathic) Gaucher's disease.
    Imiglucerase
  • HY-109527
    5-HT7 agonist 1 334974-31-1 98%
    5-HT7 agonist 1 is a selective 5-HT7 receptor agonist, with an IC50 of 222.93 nM, can be used for the 5-HT7 receptor related disease, such as CNS disorders.
    5-HT7 agonist 1
  • HY-109572
    GABAA receptor modulator-1 951654-29-8 98%
    GABAA receptor modulator-1 (9eey) is a GABAA receptor modulator that can be used in the study of central nervous system diseases.
    GABAA receptor modulator-1
  • HY-109743
    BP14979 1000036-77-0 98%
    BP14979 is a dopamine D3 receptor agonist with activity in the study of neurological diseases. BP14979 can be used to develop ligands with higher selectivity and affinity for D3 receptors. The structural characteristics of BP14979 make it potential in modulating the efficacy of D3 receptors. The design of BP14979 is based on the difference in efficacy with D3R selective antagonists, providing opportunities for optimizing new drug development.
    BP14979
  • HY-110001
    (S)-WAY 100135 dihydrochloride 149007-54-5 98%
    (S)-WAY 100135 dihydrochloride is a highly selective and potent antagonist of 5-HT 1A (IC50=33.9 nM). (S)-WAY 100135 dihydrochloride has anxiolytic activity in animal models.
    (S)-WAY 100135 dihydrochloride
  • HY-110005
    Sp-cAMPS triethylamine 93602-66-5 98%
    Sp-cAMPS triethylamine, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS triethylamine is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a Ki of 47.6 µM. Sp-cAMPS triethylamine binds the PDE10 GAF domain with an EC50 of 40 μM.
    Sp-cAMPS triethylamine
  • HY-110010
    Nafadotride 149649-22-9 98%
    Nafadotride is a dopamine D3 receptor antagonist. Nafadotrode regulates dopamine signaling primarily by antagonizing dopamine D3 receptors. The dopamine D3 receptor plays an important role in regulating emotion, motivation, reward, and certain motor functions. By blocking these receptors, Nafadotrode may affect neurotransmission processes associated with these functions. Nafadotrode can be used to explore the role of dopamine D3 receptors in various behavioral and neuropsychiatric disorders.
    Nafadotride
  • HY-110016
    Docosatetraenylethanolamide 150314-35-5 98%
    Docosatetraenylethanolamide (DEA) is a cannabinoid receptor 1 (CB1) agonist. Docosatetraenylethanolamide inhibits the specific binding of cannabinoid probe to rat synaptosomal membranes with a Ki value of 34.4 nM. Docosatetraenylethanolamide can be used in the research of nervous system.
    Docosatetraenylethanolamide
Cat. No. Product Name / Synonyms Application Reactivity